Cholangiocarcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we determined the frequency of amplification of the HER2 gene in a comprehensive and well-characterized European cholangiocarcinoma cohort encompassing 436 patients including intrahepatic (n = 155), proximal (n = 155) and distal (n = 126) cholangiocarcinoma by strict application of a combined immunohistochemical and in situ hybridization algorithm following the current guidelines for HER2 assessment in gastric cancer.
|
31805897 |
2019 |
Cholangiocarcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Cell-surface expression of HER2 was observed in both gallbladder carcinoma and cholangiocarcinoma tissues.
|
30659304 |
2019 |
Cholangiocarcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Among the newly discovered molecular alterations, targeting FGFR2 fusions, IDH1/2 mutations and HER2 receptors hold great promise for improving the future management of cholangiocarcinoma.
|
30124336 |
2018 |
Cholangiocarcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Nine patients with gallbladder cancer and five patients with cholangiocarcinoma had received HER2/neu-directed therapy (trastuzumab, lapatinib, or pertuzumab) during the study period.
|
26022204 |
2015 |
Cholangiocarcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Multiplex immunostaining/tissue cytometry and immunoprecipitation studies showed: 1) BRK co-localized with EGFR and ErbB2/neu; 2) BRK(high)/EGFR(high)-co-expressing CC cells had significantly higher Ki67 labeling and; 3) stronger BRK protein expression was seen in perihilar and distal CC than intrahepatic CC and directly correlated with CC differentiation.
|
25770659 |
2015 |
Cholangiocarcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overexpressions of EGFR and HER2 are thought to be prognostic factors of cholangiocarcinoma (CCA).
|
25181339 |
2014 |
Cholangiocarcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K.
|
20731018 |
2010 |
Cholangiocarcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Because epidermal growth factor receptor and HER-2/neu antagonists have been successfully used in adenocarcinomas from other sites, their use in cholangiocarcinoma can be potentially beneficial.
|
20040392 |
2010 |
Cholangiocarcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma.
|
18087285 |
2008 |
Cholangiocarcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Expression of c-erbB-2 proto-oncogene in extrahepatic cholangiocarcinoma and its clinical significance.
|
17690040 |
2007 |
Cholangiocarcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
HER-2/neu protein overexpression by HER-2 gene amplification may occur in human extrahepatic CC and constitute an independent prognostic factor in patients with lymph node metastases.
|
17322545 |
2007 |
Cholangiocarcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
HER-2/neu protein overexpression by HER-2 gene amplification may occur in human extrahepatic CC and constitute an independent prognostic factor in patients with lymph node metastases.
|
17322545 |
2007 |
Cholangiocarcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice.
|
16818635 |
2006 |
Cholangiocarcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer.
|
16344070 |
2005 |
Cholangiocarcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
The results also suggest ERBB-2 and COX-2 as potentially important targets relevant to chemoprevention or adjunct therapy of ChC.
|
12143054 |
2002 |
Cholangiocarcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover c-erbB-2 mRNA was not detected in seven hepatocellular carcinomas examined by Northern blot analysis. c-erbB-2 overexpression is, therefore, unlikely to be contributing to the malignant phenotype in hepatocellular carcinoma and cholangiocarcinoma.
|
1380026 |
1992 |
Cholangiocarcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expression of c-myc, c-ras, and c-erbB-2 oncogenes may be used as immunohistochemical markers to distinguish cholangiocarcinoma from nonneoplastic biliary tissues, and may provide useful information concerning the cell biology of tumor differentiation.
|
2574140 |
1989 |